The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint

World J Oncol. 2017 Apr;8(2):34-40. doi: 10.14740/wjon1019w. Epub 2017 May 4.


The AJCC Cancer Staging Manual, eighth edition published in late 2016, will become the new global guideline for cancer diagnosis and treatment from January 1, 2018. The new edition for the tumor staging system has numerous updates, including building up the prognostic stage group of tumors for the first time and adding a large number of non-anatomical factors into the prognostic evaluation. Oncotype DX and MammaPrint are two of the genomic predictors that will be part of routine clinical practice in the future. Numerous studies have proved the clinical utility of multigene panels in predicting clinical outcome and treatment response. Here we present our review of the studies on these multigene panels and their application to breast cancer.

Keywords: Breast cancer; MammaPrint; Multigene panel; Oncotype DX.

Publication types

  • Review